Dabrafenib monotherapy in BRAF+ non-small cell lung cancer - our experience
Language English Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
33685196
PII: 125207
Knihovny.cz E-resources
- Keywords
- dabrafenib – BRAF – lung cancer – non-small cell – NSCLC – monotherapy,
- MeSH
- Imidazoles therapeutic use MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Humans MeSH
- Lung Neoplasms drug therapy genetics MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy genetics MeSH
- Oximes therapeutic use MeSH
- Antineoplastic Agents therapeutic use MeSH
- Proto-Oncogene Proteins B-raf genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- dabrafenib MeSH Browser
- Imidazoles MeSH
- Protein Kinase Inhibitors MeSH
- Oximes MeSH
- Antineoplastic Agents MeSH
- Proto-Oncogene Proteins B-raf MeSH
BACKGROUND: Activating BRAF mutations result in constitutive activation of the MAP kinase signaling cascade, stimulating cell proliferation. BRAF mutations are typical for malignant melanoma, but occur less frequently in other tumors, including in 1-2% cases of non-small cell lung cancer (NSCLC) [1,2]. CASE: We present two case reports of BRAF+ NSCLC patients, treated with 3rd line dabrafenib monotherapy on our department, and also brief review of available information about dabrafenib and its use in monotherapy of BRAF+ NSCLC. CONCLUSION: Monotherapy with BRAF inhibitors presents a viable alternative for BRAF+ NSCLC patients, incapable of combined therapy with trametinib. The lack of proper indication and reimbursement for NSCLC cases remains a problem, and individual treatment approval is required.
